v-sis represents a prototype for the class of oncogenes that encode growth factors. Whether its plateletderived growth factor (PDGF)-like product functionally activates its receptors within the cell or at the cell surface has potential implications in efforts to intervene with the v-sistransformed phenotype. We demonstrate that intracellular as well as cell surface forms of two PDGF receptor gene products are tyrosine phosphorylated in v-sis transformants. In a chemically defred medium in which cell growth was dependent on v-sis expression, proliferation was partially inhibited by PDGF neutralizing antibody but completely blocked by suramin. Suramin treatment resulted in a marked reduction in tyrosine phosphorylated cell surface PDGF receptors but had no effect on the level of tyrosine phosphorylation of intracellular receptor species. All of these findings demonstrate that the vsis-encoded mitogen can bind and activate its receptors internally but that activated receptors must achieve a cell surface location in order to functionally couple with intracellular mitogenic signaling pathways.
Genes encoding growth factors and their receptors have been implicated in the regulation of normal cell growth and development. There is also increasing evidence that genetic alterations affecting expression of such genes can contribute to altered cell growth associated with malignancy. The v-sis oncogene of simian sarcoma virus encodes a growth factor homologous to the B chain of human platelet-derived growth factor (PDGFB) (1, 2) . Moreover, the normal homologues of other oncogenes code for membrane-spanning growth factor receptors (3) (4) (5) (6) . Genes that act early in intracellular pathways of growth factor signal transduction have been implicated as oncogenes as well (7) (8) (9) (10) (11) .
Intervention with the pathogenic expression of this important subset of genes might be most readily approached in the case of growth factors, if functional activation of their receptor targets in transformed cells were confined to the cell surface. Although not generally expressed by the same cells, growth factors and their receptors are often processed through the same secretory pathway (12, 13) . Moreover, in the case of the v-sis/PDGFB product, immature dimeric forms present only within the cell have been shown to have mitogenic potential (14) . Efforts to date to localize the critical site(s) for functional interaction of the v-sis-encoded mitogen with PDGF receptors (PDGFRs) have led to contradictory conclusions. Available evidence argues either that mitogenically active v-sis gene products bind and activate PDGFRs during processing within the cell (15) (16) (17) or that functional interaction occurs only after these molecules achieve a cell surface location (18, 19) . Our present studies resolve this controversy by establishing the specific sites of receptor activation and functional coupling with mitogenic signal transduction pathways. These findings have general implications concerning localization within the cell of critical targets ofgrowth factor receptor action as well as approaches toward intervention with autocrine-associated malignancies.
MATERIALS AND METHODS
Cells and Reagents. NIH 3T3 mouse embryonic fibroblasts (20) and the transformed derivatives sis/3T3 (21) and erbB-2 (22) were established in this laboratory. PDGF BB homodimer (PDGF-BB) was purchased from Amgen Biologicals. Suramin was obtained from the Division of Cancer Treatment, National Cancer Institute.
DNA Synthesis Assay. DNA synthesis was measured as described elsewhere (23) with a few modifications. Twentyfour-well Costar plates were precoated with human fibronectin (Collaborative Research) at 1 ug/cm2 prior to seeding the cells. Serum-free growth media consisted of a mixture of MCDB 401 medium (Irvine Scientific), Leibovitz's L-15 medium (GIBCO), and Ham's F12 medium (BioFluids, Rockville, MD) containing 10 nM selenium (GIBCO) and 10 tug of transferrin per ml (Collaborative Research).
Colony Formation in Soft Agar. Around 104 cells were plated in 0.4% agarose suspension (SeaPlaque, FMC) in Dulbecco's modified Eagle's medium as described elsewhere (24) . Colonies were scored at 14 days.
Analysis of Tyrosine Phosphorylated a and (3 PDGFRs. Western analysis of cell lysates was performed as described (25) . Briefly, cells were lysed with Staph-A buffer (10 mM sodium phosphate, pH 7.5/100 mM NaCl, 1% Triton X-100/ 0.1% SDS, 0.5% deoxycholate/0.1% aprotinin/1 mM phenylmethylsulfonyl fluoride/i mM sodium orthovanadate) and clarified by centrifugation at 10,000 x g for 30 min. Lysates were immunoprecipitated with peptide antisera specific for either a or P PDGFRs or anti-phosphotyrosine serum as described (25) . Immunoprecipitates were subjected to SDS/polyacrylamide gel electrophoresis, blotted onto nitrocellulose filters, and treated with affinity-purified antiphosphotyrosine serum (25 Fig. 1 A-C) . Moreover, such cells formed colonies in soft agar at an efficiency comparable to that ofv-sis transformants (Fig. 1 D-F E tional activity of the v-sis product was susceptible at least in part to intervention at the cell surface.
Immature and Fully Processed Forms of a and .8 PDGFRs
Are Activated in v-sis-Transformed Cells. Recent investigations have demonstrated that two independent genes encode PDGFRs (25) . The newly identified a PDGFR gene product can be tyrosine phosphorylated in response to all three PDGF isoforms including AA, AB, and BB, whereas the previously identified 3PDGFR gene product does not appear to interact with the AA isoform (25) (26) (27) . To investigate PDGFR gene products chronically activated in v-sis-transformed cells, we took advantage of antibodies specific for each receptor (25) . Cell lysates from control NIH 3T3 cells, either quiescent or stimulated for 5 min or 18 hr with PDGF-BB, as well as from v-sis-transformed NIH 3T3 cells, were subjected to Western blotting analysis with either anti-a or -(3 PDGFR serum. In addition, cell lysates specifically enriched for the respective receptors by immunoprecipitation were subjected to Western blotting analysis using anti-phosphotyrosine serum.
As shown in Fig. 3 , NIH 3T3 cells contained 180-and 160-kDa forms of the a receptor and 180-and 165-kDa forms of the /3 receptor. Other studies have shown that the respective lower molecular weight forms represent immature receptor species, whereas the higher molecular weight species represent fully processed, cell surface receptors (refs. 15 and 16; T.P.F., unpublished data). PDGF stimulation led to a detectable shift in electrophoretic mobility of the cell surface a and 3receptors and to significant down-regulation of each by 18 hr (Fig. 3) .
Although there was no detectable tyrosine phosphorylation of either receptor in quiescent NIH 3T3 cells, PDGF-BB addition led to a rapid and striking increase in tyrosine phosphorylation of both cell surface a and /3 receptors. Under these same conditions, there was no detectable tyrosine phosphorylation of immature forms of either receptors. By 18 hr, the level of tyrosine phosphorylated surface a and P receptors was significantly reduced, consistent with the reduction in receptor protein (Fig. 3) . In v-sis-transformed NIH 3T3 cells, we observed tyrosine phosphorylated cell surface a and 83 receptors at levels approximating those in NIH 3T3 cells exposed for 18 hr to PDGF-BB (Fig. 3) . Of note, the v-sis-transformed cells also contained detectable tyrosine phosphorylated immature forms of both receptors (Fig. 3) , indicating activation of immature as well as mature forms of both PDGFR gene products in these cells.
Functional Coupling of Activated Receptors with PDGF Mitogenic Pathways Is Confined to the Cell Surface. Suramin is a highly anionic naphthalene sulfonic acid derivative (28) , which has previously been reported to inhibit PDGF mitogenic activity and to induce transient reversion of the vsis-transformed phenotype (29) . However, evidence that suramin may act within the cell (30) as well as externally has led to controversy concerning its site of action (15, 29) . We first investigated the ability of suramin to inhibit vsis-directed cell proliferation utilizing the chemically defined system described above. As shown in Fig. 4A , suramin led to a striking and very similar dose-dependent inhibition of DNA synthesis by v-sis-transformed cells and exogenous PDGF-BB-stimulated NIH 3T3 cells. As a control, suramin failed to inhibit DNA synthesis by erbB-2-transformed cells under the same conditions. The inhibitory effect of suramin on exogenous PDGF-or v-sis-directed proliferation was also apparent in a time course study (Fig. 4B) , where inhibition in each case was >95% over 72 hr. All of these findings demonstrated that suramin was a more potent inhibitor than PDGF antibody of v-sis-directed growth. To establish the site at which suramin blocked function of the v-sis product, we exposed v-sis-transformed cells to suramin for 24 hr. Cell lysates were then subjected to Western analysis using anti-phosphotyrosine serum after enriching for tyrosine phosphorylated proteins by immunoprecipitation with the same antiserum. In untreated vsis-transformed cells, the mature tyrosine phosphorylated forms of both PDGFR gene products migrated at around 180 kDa (Fig. SA) , and 165-and 160-kDa immature forms of the a and ,3 receptors, respectively, were readily detected as well (Fig. SA, lane 2) . Exposure of the same cells to 100 juM suramin for 24 hr led to a marked diminution in the level of tyrosine phosphorylated cell surface PDGFRs. In striking contrast, suramin had no effect on the level of tyrosine phosphorylated, intracellular a or P PDGFR species (Fig. 5A,   lane 3) . At the same time, there was an increase in the actual levels of both a and P PDGFR surface proteins detected immunologically with either receptor antibody (Fig. 5B) , reflecting surface receptor up-regulation in the presence of suramin. These results established that suramin intervened with interaction of the v-sis product and its receptors but that suramin action was specifically localized to cell surface PDGFRs. Thus, we conclude that although the v-sis gene product activates both PDGFR gene products during processing intracellularly within the secretory pathway, functional coupling of activated receptors with mitogenic signaling pathways requires their cell surface localization.
DISCUSSION
Efforts to establish whether autocrine growth stimulation can be blocked by surface-specific antagonists have intensified with evidence for involvement of such mechanisms in an increasing array of naturally occurring tumors (31) (32) (33) (34) as well as other chronic diseases (35- sis/PDGFB has been extensively investigated as a prototype for autocrine mechanisms of neoplastic transformation. Previous efforts to localize the site of v-sis action have led to conflicting findings and conclusions. Antibody to PDGF has been reported to inhibit growth of v-sis transformants to various extents, consistent with at least some surface component to activity of the v-sis product (17, 18) . Moreover, Hannick and Donaghue (19) reported that v-sis products that failed to achieve a cell surface lacked transforming activity. Proc. Natl. Acad. Sci. USA 86 (1989) In contrast, others have reported evidence that internal forms of the PDGFR are tyrosine phosphorylated and exhibit greatly increased turnover in the absence of detectable mature PDGFR species (15, 16) . This has led to a so-called "internal autocrine" model, implying that receptor activation and functional coupling with mitogenic pathways occur entirely within the cell (15, 16) .
In the present studies, we demonstrated that exogenous PDGF can induce growth alterations that mimic the v-sistransformed state. These findings establish Our evidence that the functional coupling of activated PDGFRs with intracellular mitogenic signaling pathways in NIH 3T3 cells requires their cell surface localization strongly suggests that critical targets of receptor action may be specifically located at or near the inner surface of the cell membrane. Alternatively, events associated with internalization of activated receptors may be critical for effective receptor signaling. The v-fms product represents an activated form of the colony-stimulating factor 1 (CSF-1) receptor (4, 38) , which is structurally related to the PDGFRs (25, 39) . Certain glycosylation inhibitors have been reported to induce reversion of v-fms-transformed cells associated with a lack of maturation of the v-fms product (40 
